zealand
pharma
increases
share
capital
consequence
exercise
employee
warrants
company
announcement
zealand
pharma
increases
share
capital
consequence
exercise
employee
warrants
copenhagen
september
zealand
pharma
zealand
nasdaq
zeal
biotechnology
company
focused
discovery
development
innovative
medicines
increased
share
capital
nominal
amount
dkk
divided
new
shares
nominal
value
dkk
increase
consequence
exercise
warrants
granted
several
zealand
employee
warrant
programs
employee
warrant
programs
part
zealand
incentive
scheme
warrant
gives
owner
right
subscribe
one
new
zealand
share
pre
specified
price
exercise
price
specific
predefined
time
periods
expiration
detailed
description
zealand
warrant
programs
see
company
articles
association
available
website
exercise
price
dkk
per
share
new
shares
dkk
per
share
new
shares
total
proceeds
zealand
capital
increase
amount
dkk
new
shares
give
rights
dividend
rights
time
warrant
holder
exercise
notice
new
share
carries
one
vote
zealand
general
meetings
zealand
one
class
shares
new
shares
listed
nasdaq
copenhagen
registration
capital
increase
danish
business
authority
following
registration
new
shares
share
capital
zealand
nominal
dkk
divided
shares
nominal
value
dkk
amendment
zealand
articles
association
entailed
share
capital
increase
today
registered
danish
business
authority
zealand
pharma
zealand
pharma
nasdaq
zeal
zealand
biotechnology
company
focused
discovery
development
commercialization
innovative
medicines
drug
candidates
invented
zealand
advanced
clinical
development
two
reached
market
zealand
robust
pipeline
investigational
medicines
includes
three
candidates
late
stage
development
one
candidate
reviewed
regulatory
approval
united
states
zealand
markets
insulin
delivery
option
people
diabetes
license
collaborations
boehringer
ingelheim
alexion
pharmaceuticals
create
opportunity
patients
potentially
benefit
peptide
therapeutics
zealand
founded
copenhagen
denmark
presence
throughout
includes
key
locations
new
york
boston
marlborough
information
zealand
business
activities
please
visit
statement
information
contains
statements
provide
zealand
pharma
expectations
forecasts
future
events
statements
subject
risks
uncertainties
inaccurate
assumptions
may
cause
actual
results
differ
materially
expectations
set
forth
herein
may
cause
statements
incorrect
statements
prove
incorrect
actual
results
could
differ
materially
adversely
anticipated
implied
statements
statements
speak
date
release
based
information
available
zealand
pharma
date
release
information
please
contact
mads
kronborg
head
investor
relations
communication
phone
email
mkronborg
media
david
rosen
argot
partners
phone
email
media
